- Conditions
- RUNX1 Familial Platelet Disorder
- Interventions
- G-CSF (filgrastim or biosimilar), Apheresis, Plerixafor
- Drug · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Lymphoma, Non-Hodgkin, Multiple Myeloma
- Interventions
- G-CSF Plus Plerixafor
- Drug
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 8
- States / cities
- Little Rock, Arkansas • Loa Angeles, California • Maywood, Illinois + 5 more
- Conditions
- Myelomeningocele
- Interventions
- Placental Mesenchymal Stem Cells seeded on a commercially available dural graft extracellular matrix, Untreated contemporaneous cohort
- Biological · Other
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 19 Weeks to 25 Weeks
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Chronic Low Back Pain, Degenerative Disc Disease
- Interventions
- Autologous stem cells, Corticosteroid, Local anesthetic
- Other · Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 100 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Astrocytoma, Glioblastoma, Progressive Disease
- Interventions
- FT536, Biopsy/ Intratumoral Injection/ Gross Tumor Resection, Blood/ Cerebrospinal Fluid/ Tumor Pathology
- Biological · Procedure · Diagnostic Test
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Craniocervical Injuries
- Interventions
- Alar treatment with BMC using anterior approach
- Procedure
- Lead sponsor
- Regenexx, LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Broomfield, Colorado
- Conditions
- Lower Limb Ischemia
- Interventions
- Neupogen, Art-Assist Device
- Drug · Device
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 40 Years to 85 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- FANCONI ANEMIA
- Interventions
- CD34 selected haploidentical PBSCT, Fludarabine, T cell infusion, Campath 1h, anti-CD45
- Procedure · Drug · Biological
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- Up to 64 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2002 – 2009
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Sickle Cell Disease
- Interventions
- Plerixafor, Busulfan, BIVV003
- Biological · Drug · Genetic
- Lead sponsor
- Sangamo Therapeutics
- Industry
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 5
- States / cities
- Oakland, California • Sacramento, California • Atlanta, Georgia + 2 more
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndrome, Chronic Myeloid Leukemia
- Interventions
- Clofarabine, Busulfan, Fludarabine, Stem Cell Infusion, Thymoglobulin (ATG), Filgrastim
- Drug · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Up to 60 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2013
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Stem Cells, Orthopedic Disorder
- Interventions
- Filgrastim Injection
- Drug
- Lead sponsor
- Andrews Research & Education Foundation
- Other
- Eligibility
- 19 Years to 39 Years · Male only
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Auburn, Alabama
- Conditions
- HLHS
- Interventions
- Longeveron Mesenchymal Stem Cells
- Biological
- Lead sponsor
- Longeveron Inc.
- Industry
- Eligibility
- 1 Day to 1 Year
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 5
- States / cities
- Atlanta, Georgia • Baltimore, Maryland • Cincinnati, Ohio + 1 more
- Conditions
- Pelizaeus-Merzbacher Disease
- Interventions
- HuCNS-SC cells
- Biological
- Lead sponsor
- StemCells, Inc.
- Industry
- Eligibility
- 6 Months to 5 Years · Male only
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Stargardt's Macular Dystrophy
- Interventions
- MA09-hRPE
- Biological
- Lead sponsor
- Astellas Institute for Regenerative Medicine
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Miami, Florida • Philadelphia, Pennsylvania
- Conditions
- Refractory Angina, Chronic Myocardial Ischemia
- Interventions
- CardiAMP Cell Therapy System, Sham Treatment
- Device · Other
- Lead sponsor
- BioCardia, Inc.
- Industry
- Eligibility
- 21 Years to 80 Years
- Enrollment
- 343 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 2
- States / cities
- Gainesville, Florida • Madison, Wisconsin
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Adult T-Cell Leukemia/Lymphoma, Aplastic Anemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, BCR-ABL1 Positive, Chronic Myelomonocytic Leukemia, Essential Thrombocythemia, Hematopoietic and Lymphatic System Neoplasm, Hodgkin Lymphoma, Multiple Myeloma, Myelodysplastic Syndrome, Myelofibrosis, Myeloid Neoplasm, Non-Hodgkin Lymphoma, Polycythemia Vera, Small Lymphocytic Lymphoma
- Interventions
- Fludarabine, Total-Body Irradiation, Donor Lymphocyte Infusion, Cyclophosphamide, Tacrolimus, Mycophenolate Mofetil, Hematopoietic Cell Transplantation, Melphalan, Bone Marrow Aspiration and Biopsy, Diagnostic Imaging, Biospecimen Collection
- Drug · Radiation · Procedure
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2032
- U.S. locations
- 1
- States / cities
- Philadephia, Pennsylvania
- Conditions
- Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1, Adult Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A, Untreated Adult Acute Myeloid Leukemia
- Interventions
- Autologous Bone Marrow Transplantation, Autologous Hematopoietic Stem Cell Transplantation, Busulfan, Cytarabine, Daunorubicin Hydrochloride, Decitabine, Etoposide, Filgrastim, Laboratory Biomarker Analysis, Pharmacological Study
- Procedure · Drug · Biological + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 15 Years to 59 Years
- Enrollment
- 546 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2016
- U.S. locations
- 46
- States / cities
- San Francisco, California • Lewes, Delaware • Newark, Delaware + 35 more
- Conditions
- Stem Cell Transplantation
- Interventions
- Fludarabine, Dexamethasone, Cyclophosphamide, Bortezomib, Rituximab, Busulfan, Cyclophosphamide (Cy), Tacrolimus (or cyclosporine), Mycophenolate mofetil (MMF), Rabbit ATG
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Amyotrophic Lateral Sclerosis (ALS)
- Interventions
- NurOwn® (MSC-NTF cells), Placebo, Bone Marrow aspiration
- Biological · Other
- Lead sponsor
- Brainstorm-Cell Therapeutics
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 196 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 6
- States / cities
- Irvine, California • Los Angeles, California • San Francisco, California + 3 more
- Conditions
- Facet-Mediated Low Back Pain
- Interventions
- Single bilateral intra-articular injection of allogeneic BM-MSCs for lumbar facet joint arthropathy
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 40 Years to 70 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- MyoPAXon, Tacrolimus
- Drug
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Relapsed Neuroblastoma, Metastatic Pheochromocytoma
- Interventions
- 131 I-Metaiodobenzylguanidine (131I-MIBG), Potassium iodide solution, G-CSF, hematopoietic stem cell infusion
- Drug · Procedure
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- 1 Year and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2025
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Osteosarcoma, Bone Metastases
- Interventions
- 153Sm-DOTMP, External beam radiotherapy., Calcium Carbonate, Mozobil, Neupogen Injectable Product
- Drug · Radiation
- Lead sponsor
- Albert Einstein College of Medicine
- Other
- Eligibility
- 15 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Corneal Ulcer
- Interventions
- Mesenchymal Stromal Cells, Control Solution
- Biological · Other
- Lead sponsor
- University of Illinois at Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Baltimore, Maryland • Boston, Massachusetts + 1 more